{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:30Z","timestamp":1787002830837,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/nrurol.2015.169","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T05:51:04Z","timestamp":1437457864000},"page":"461-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["New intraprostatic injectables and prostatic urethral lift for male LUTS"],"prefix":"10.1038","volume":"12","author":[{"given":"Giuseppe","family":"Magistro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"BFnrurol2015169_CR1","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.juro.2009.06.047","volume":"182","author":"S Loeb","year":"2009","unstructured":"Loeb, S. et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J. Urol. 182, 1458\u20131462 (2009).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/pros.20663","volume":"67","author":"JL Bosch","year":"2007","unstructured":"Bosch, J. L., Tilling, K., Bohnen, A. M., Bangma, C. H. & Donovan, J. L. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate 67, 1816\u20131824 (2007).","journal-title":"Prostate"},{"issue":"Suppl. 3","key":"BFnrurol2015169_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","volume":"101","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn, C. G. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 101 (Suppl. 3), 17\u201321 (2008).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.juro.2010.01.026","volume":"183","author":"JK Parsons","year":"2010","unstructured":"Parsons, J. K. et al. Progression of lower urinary tract symptoms in older men: a community based study. J. Urol. 183, 1915\u20131920 (2010).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.urology.2006.04.019","volume":"68","author":"BC Taylor","year":"2006","unstructured":"Taylor, B. C. et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 68, 804\u2013809 (2006).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.eururo.2007.08.042","volume":"53","author":"JL Bosch","year":"2008","unstructured":"Bosch, J. L., Bangma, C. H., Groeneveld, F. P. & Bohnen, A. M. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur. Urol. 53, 819\u2013825 (2008).","journal-title":"Eur. Urol."},{"issue":"Suppl.","key":"BFnrurol2015169_CR7","first-page":"S75","volume":"179","author":"JT Wei","year":"2008","unstructured":"Wei, J. T., Calhoun, E. & Jacobsen, S. J. Urologic diseases in America project: benign prostatic hyperplasia. J. Urol. 179 (Suppl.), S75\u2013S80 (2008).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-5347(17)35405-8","volume":"150","author":"CG Chute","year":"1993","unstructured":"Chute, C. G. et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J. Urol. 150, 85\u201389 (1993).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke, C. et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur. Urol. 67, 1099\u20131109 (2015).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR10","volume-title":"auanet.org","author":"KT McVary","year":"2010","unstructured":"McVary, K. T. et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). auanet.org [online] (2010)."},{"key":"BFnrurol2015169_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.mcna.2010.08.013","volume":"95","author":"CG Roehrborn","year":"2011","unstructured":"Roehrborn, C. G. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med. Clin. North Am. 95, 87\u2013100 (2011).","journal-title":"Med. Clin. North Am."},{"key":"BFnrurol2015169_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","volume":"44","author":"KM Verhamme","year":"2003","unstructured":"Verhamme, K. M. et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur. Urol. 44, 539\u2013545 (2003).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR13","volume-title":"guideline.gov","author":"CG Roehrborn","year":"2003","unstructured":"Roehrborn, C. G. et al. American Urological Association Guideline: Management of benign prostatic hyperplasia (BPH). guideline.gov [online] , (2003)."},{"key":"BFnrurol2015169_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0090-4295(94)80208-4","volume":"44","author":"GL Lu-Yao","year":"1994","unstructured":"Lu-Yao, G. L., Barry, M. J., Chang, C. H., Wasson, J. H. & Wennberg, J. E. Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 44, 692\u2013698 (1994).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0022-5347(17)32762-3","volume":"152","author":"JD McConnell","year":"1994","unstructured":"McConnell, J. D. Benign prostatic hyperplasia. J. Urol. 152, 459\u2013460 (1994).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0094-0143(21)00664-9","volume":"22","author":"E Shapiro","year":"1995","unstructured":"Shapiro, E. & Lepor, H. Pathophysiology of clinical benign prostatic hyperplasia. Urol. Clin. North Am. 22, 285\u2013290 (1995).","journal-title":"Urol. Clin. North Am."},{"key":"BFnrurol2015169_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","volume":"49","author":"CR Chapple","year":"2006","unstructured":"Chapple, C. R. & Roehrborn, C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur. Urol. 49, 651\u2013658 (2006).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11934-002-0095-3","volume":"3","author":"KF Abdel-Aziz","year":"2002","unstructured":"Abdel-Aziz, K. F. & Lemack, G. E. Overactive bladder in the male patient: bladder, outlet, or both? Curr. Urol. Rep. 3, 445\u2013451 (2002).","journal-title":"Curr. Urol. Rep."},{"key":"BFnrurol2015169_CR19","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/01.ju.0000139987.77928.da","volume":"172","author":"MB Siroky","year":"2004","unstructured":"Siroky, M. B. Lower urinary tract symptoms: shifting our focus from the prostate to the bladder. J. Urol. 172, 1237\u20131238 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2009.07.044","volume":"56","author":"A Roosen","year":"2009","unstructured":"Roosen, A. et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur. Urol. 56, 810\u2013819 (2009).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR21","doi-asserted-by":"publisher","first-page":"E524","DOI":"10.5489\/cuaj.1636","volume":"8","author":"C Komninos","year":"2014","unstructured":"Komninos, C. & Mitsogiannis, I. Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology. Can. Urol. Assoc. J. 8, E524\u2013E530 (2014).","journal-title":"Can. Urol. Assoc. J."},{"key":"BFnrurol2015169_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJM199608223350809","volume":"335","author":"PC Walsh","year":"1996","unstructured":"Walsh, P. C. Treatment of benign prostatic hyperplasia. N. Engl. J. Med. 335, 586\u2013587 (1996).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"BFnrurol2015169_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1464-410X.1998.0810s1029.x","volume":"81","author":"H Lepor","year":"1998","unstructured":"Lepor, H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br. J. Urol. 81 (Suppl. 1), 29\u201333 (1998).","journal-title":"Br. J. Urol."},{"key":"BFnrurol2015169_CR24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S0022-3565(25)10683-6","volume":"274","author":"MR Ruggieri","year":"1995","unstructured":"Ruggieri, M. R. et al. Human prostate muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 274, 976\u2013982 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2015169_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1046\/j.1365-2680.2000.00195.x","volume":"20","author":"JN Pennefather","year":"2000","unstructured":"Pennefather, J. N., Lau, W. A., Mitchelson, F. & Ventura, S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J. Auton Pharmacol. 20, 193\u2013206 (2000).","journal-title":"J. Auton Pharmacol."},{"key":"BFnrurol2015169_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0163-7258(02)00174-2","volume":"94","author":"S Ventura","year":"2002","unstructured":"Ventura, S., Pennefather, J. & Mitchelson, F. Cholinergic innervation and function in the prostate gland. Pharmacol. Ther. 94, 93\u2013112 (2002).","journal-title":"Pharmacol. Ther."},{"key":"BFnrurol2015169_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1476-5381.1988.tb10329.x","volume":"93","author":"N Seki","year":"1988","unstructured":"Seki, N., Nishiye, E., Itoh, T., Suzuki, H. & Kuriyama, H. Electrical and mechanical properties of the capsular smooth muscles of the rabbit prostate in relation to the actions of the alpha 1-adrenoceptor blocker, YM-12617. Br. J. Pharmacol. 93, 702\u2013714 (1988).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2015169_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0022-5347(17)53216-4","volume":"128","author":"S Furuya","year":"1982","unstructured":"Furuya, S. et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J. Urol. 128, 836\u2013839 (1982).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/j.1939-4640.2001.tb02199.x","volume":"22","author":"N Ravindranath","year":"2001","unstructured":"Ravindranath, N., Wion, D., Brachet, P. & Djakiew, D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl. 22, 432\u2013443 (2001).","journal-title":"J. Androl."},{"key":"BFnrurol2015169_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/pros.10170","volume":"54","author":"D Marinese","year":"2003","unstructured":"Marinese, D., Patel, R. & Walden, P. D. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54, 230\u2013237 (2003).","journal-title":"Prostate"},{"key":"BFnrurol2015169_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00307937","volume":"23","author":"PJ Gkonos","year":"1995","unstructured":"Gkonos, P. J., Krongrad, A. & Roos, B. A. Neuroendocrine peptides in the prostate. Urol. Res. 23, 81\u201387 (1995).","journal-title":"Urol. Res."},{"key":"BFnrurol2015169_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0046-8177(96)90002-7","volume":"21","author":"H Price","year":"1990","unstructured":"Price, H., McNeal, J. E. & Stamey, T. A. Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Pathol. 21, 578\u2013585 (1990).","journal-title":"Hum. Pathol."},{"key":"BFnrurol2015169_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4103\/0970-1591.42613","volume":"24","author":"AM Saemi","year":"2008","unstructured":"Saemi, A. M., Folsom, J. B., Plante, M. K. Injection therapy for prostatic disease: A renaissance concept. Indian J. Urol. 24, 329\u2013335 (2008).","journal-title":"Indian J. Urol."},{"key":"BFnrurol2015169_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MOU.0b013e3282f20169","volume":"18","author":"AM Saemi","year":"2008","unstructured":"Saemi, A. M. & Plante, M. K. Injectables in the prostate. Curr. Opin. Urol. 18, 28\u201333 (2008).","journal-title":"Curr. Opin. Urol."},{"key":"BFnrurol2015169_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/00365599.2012.752404","volume":"47","author":"KE Andersson","year":"2013","unstructured":"Andersson, K. E. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand. J. Urol. 47, 83\u201390 (2013).","journal-title":"Scand. J. Urol."},{"issue":"Suppl. 8","key":"BFnrurol2015169_CR36","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1002\/mds.20003","volume":"19","author":"FJ Erbguth","year":"2004","unstructured":"Erbguth, F. J. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov. Disord. 19 (Suppl. 8), S2\u2013S6 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrurol2015169_CR37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","volume":"139","author":"DD Dykstra","year":"1988","unstructured":"Dykstra, D. D., Sidi, A. A., Scott, A. B., Pagel, J. M. & Goldish, G. D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 139, 919\u2013922 (1988).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty, G. et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review. Eur. Urol. 53, 275\u2013287 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR39","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.urology.2004.06.073","volume":"64","author":"CP Smith","year":"2004","unstructured":"Smith, C. P. et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64, 871\u2013875 (2004).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR40","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/01.ju.0000049202.56189.54","volume":"169","author":"CP Smith","year":"2003","unstructured":"Smith, C. P. et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J. Urol. 169, 1896\u20131900 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR41","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1073\/pnas.85.20.7820","volume":"85","author":"BS De","year":"1988","unstructured":"De, B. S. & Rustioni, A. Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc. Natl Acad. Sci. USA 85, 7820\u20137824 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrurol2015169_CR42","doi-asserted-by":"publisher","first-page":"34846","DOI":"10.1074\/jbc.M202902200","volume":"277","author":"MJ Duggan","year":"2002","unstructured":"Duggan, M. J. et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. 277, 34846\u201334852 (2002).","journal-title":"J. Biol. Chem."},{"key":"BFnrurol2015169_CR43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki, K. R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type, A. Neurotoxicology 26, 785\u2013793 (2005).","journal-title":"Neurotoxicology"},{"key":"BFnrurol2015169_CR44","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.juro.2006.07.127","volume":"176","author":"YC Chuang","year":"2006","unstructured":"Chuang, Y. C. & Chancellor, M. B. The application of botulinum toxin in the prostate. J. Urol. 176, 2375\u20132382 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR45","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/0306-4522(82)90056-2","volume":"7","author":"I MacKenzie","year":"1982","unstructured":"MacKenzie, I., Burnstock, G. & Dolly, J. O. The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7, 997\u20131006 (1982).","journal-title":"Neuroscience"},{"key":"BFnrurol2015169_CR46","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","volume":"175","author":"DE Rapp","year":"2006","unstructured":"Rapp, D. E., Turk, K. W., Bales, G. T. & Cook, S. P. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 175, 1138\u20131142 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR47","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0165-6147(94)90147-3","volume":"15","author":"A Dray","year":"1994","unstructured":"Dray, A., Urban, L. & Dickenson, A. Pharmacology of chronic pain. Trends Pharmacol. Sci. 15, 190\u2013197 (1994).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrurol2015169_CR48","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1097\/01.ju.0000127725.48479.89","volume":"171","author":"CP Smith","year":"2004","unstructured":"Smith, C. P. & Chancellor, M. B. Emerging role of botulinum toxin in the management of voiding dysfunction. J. Urol. 171, 2128\u20132137 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR49","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","volume":"172","author":"YC Chuang","year":"2004","unstructured":"Chuang, Y. C., Yoshimura, N., Huang, C. C., Chiang, P. H. & Chancellor, M. B. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 172, 1529\u20131532 (2004).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8","volume":"37","author":"R Doggweiler","year":"1998","unstructured":"Doggweiler, R., Zermann, D. H., Ishigooka, M. & Schmidt, R. A. Botox-induced prostatic involution. Prostate 37, 44\u201350 (1998).","journal-title":"Prostate"},{"key":"BFnrurol2015169_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2490-6-12","volume":"6","author":"YC Chuang","year":"2006","unstructured":"Chuang, Y. C. et al. Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol. 6, 12 (2006).","journal-title":"BMC Urol."},{"key":"BFnrurol2015169_CR52","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2008.07.003","volume":"56","author":"J Silva","year":"2009","unstructured":"Silva, J. et al. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur. Urol. 56, 134\u2013140 (2009).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR53","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/sj.pcan.4500561","volume":"5","author":"IE Anglin","year":"2002","unstructured":"Anglin I E., Glassman, D. T. & Kyprianou, N. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 5, 88\u201395 (2002).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"BFnrurol2015169_CR54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1095\/biolreprod51.1.99","volume":"51","author":"KT McVary","year":"1994","unstructured":"McVary, K. T. et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol. Reprod. 51, 99\u2013107 (1994).","journal-title":"Biol. Reprod."},{"key":"BFnrurol2015169_CR55","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S0022-5347(05)00318-6","volume":"175","author":"YC Chuang","year":"2006","unstructured":"Chuang, Y. C. et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J. Urol. 175, 1158\u20131163 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR56","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2007.03.002","volume":"52","author":"AT Lin","year":"2007","unstructured":"Lin, A. T., Yang, A. H. & Chen, K. K. Effects of botulinum toxin A on the contractile function of dog prostate. Eur. Urol. 52, 582\u2013589 (2007).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR57","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera, A. et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 60, 784\u2013795 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR58","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.eururo.2013.10.033","volume":"65","author":"A Mangera","year":"2014","unstructured":"Mangera, A. et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur. Urol. 65, 981\u2013990 (2014).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/MOU.0b013e328333ac01","volume":"20","author":"A Oeconomou","year":"2010","unstructured":"Oeconomou, A. & Madersbacher, H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr. Opin. Urol. 20, 28\u201336 (2010).","journal-title":"Curr. Opin. Urol."},{"key":"BFnrurol2015169_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/MOU.0b013e3283410117","volume":"21","author":"E Chartier-Kastler","year":"2011","unstructured":"Chartier-Kastler, E., Mehnert, U., Denys, P. & Giuliano, F. Botulinum neurotoxin A for male lower urinary tract symptoms. Curr. Opin. Urol. 21, 13\u201321 (2011).","journal-title":"Curr. Opin. Urol."},{"key":"BFnrurol2015169_CR61","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.eururo.2008.06.016","volume":"54","author":"A Oeconomou","year":"2008","unstructured":"Oeconomou, A. et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur. Urol. 54, 765\u2013775 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR62","doi-asserted-by":"publisher","unstructured":"Arnouk, R. et al. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal [online] , (2012).","DOI":"10.1100\/2012\/463574"},{"key":"BFnrurol2015169_CR63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.juro.2011.04.062","volume":"186","author":"ED Crawford","year":"2011","unstructured":"Crawford, E. D. et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J. Urol. 186, 965\u2013970 (2011).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR64","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","volume":"63","author":"M Marberger","year":"2013","unstructured":"Marberger, M. et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur. Urol. 63, 496\u2013503 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR65","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","volume":"98","author":"YC Chuang","year":"2006","unstructured":"Chuang, Y. C., Chiang, P. H., Yoshimura, N., De, M. F. & Chancellor, M. B. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 98, 1033\u20131037 (2006).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR66","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/00365590902811537","volume":"43","author":"HC Kuo","year":"2009","unstructured":"Kuo, H. C. & Liu, H. T. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand. J. Urol. Nephrol. 43, 206\u2013211 (2009).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"BFnrurol2015169_CR67","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3349\/ymj.2006.47.5.706","volume":"47","author":"DS Park","year":"2006","unstructured":"Park, D. S. et al. Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med. J. 47, 706\u2013714 (2006).","journal-title":"Yonsei Med. J."},{"key":"BFnrurol2015169_CR68","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00345-012-0851-z","volume":"31","author":"MA Hamidi","year":"2013","unstructured":"Hamidi, M. A. et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J. Urol. 31, 235\u2013239 (2013).","journal-title":"World J. Urol."},{"key":"BFnrurol2015169_CR69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","volume":"62","author":"G Maria","year":"2003","unstructured":"Maria, G. et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62, 259\u2013264 (2003).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR70","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2008.08.475","volume":"73","author":"G Brisinda","year":"2009","unstructured":"Brisinda, G. et al. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73, 90\u201394 (2009).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR71","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.urology.2005.04.029","volume":"66","author":"YC Chuang","year":"2005","unstructured":"Chuang, Y. C., Chiang, P. H., Huang, C. C., Yoshimura, N. & Chancellor, M. B. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66, 775\u2013779 (2005).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR72","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.urology.2004.10.077","volume":"65","author":"HC Kuo","year":"2005","unstructured":"Kuo, H. C. Prostate botulinum A toxin injection\u2014an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65, 670\u2013674 (2005).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR73","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.urology.2012.06.004","volume":"80","author":"LM de Kort","year":"2012","unstructured":"de Kort, L. M., Kok, E. T., Jonges, T. N., Rosier, P. F. & Bosch, J. L. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology 80, 889\u2013893 (2012).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/00365591003649201","volume":"44","author":"M Nikoobakht","year":"2010","unstructured":"Nikoobakht, M. et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport. Scand. J. Urol. Nephrol. 44, 151\u2013157 (2010).","journal-title":"Scand. J. Urol. Nephrol."},{"key":"BFnrurol2015169_CR75","doi-asserted-by":"publisher","first-page":"E837","DOI":"10.1111\/j.1464-410X.2012.11288.x","volume":"110","author":"E Sacco","year":"2012","unstructured":"Sacco, E. et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int. 110, E837\u2013E844 (2012).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR76","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eururo.2007.08.050","volume":"53","author":"J Silva","year":"2008","unstructured":"Silva, J. et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur. Urol. 53, 153\u2013159 (2008).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2490-9-9","volume":"9","author":"J Silva","year":"2009","unstructured":"Silva, J. et al. Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol. 9, 9 (2009).","journal-title":"BMC Urol."},{"key":"BFnrurol2015169_CR78","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/j.1464-410X.2010.09841.x","volume":"107","author":"J Silva","year":"2011","unstructured":"Silva, J. et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int. 107, 1950\u20131954 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR79","first-page":"291","volume":"66","author":"T Yokoyama","year":"2012","unstructured":"Yokoyama, T., Yamamoto, Y., Suzuki, T., Oguma, K. & Nagai, A. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin. Acta Med. Okayama 66, 291\u2013297 (2012).","journal-title":"Acta Med. Okayama"},{"key":"BFnrurol2015169_CR80","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","volume":"49","author":"RC Rosen","year":"1997","unstructured":"Rosen, R. C. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49, 822\u2013830 (1997).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR81","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0022-5347(09)61491-9","volume":"181","author":"R Bruskewitz","year":"2009","unstructured":"Bruskewitz, R. et al. Changes in sexual function in men randomized into a two-stage phase II trial of 100 and 300 units of botulinum neurotoxin type A (BONT-A) for the management of benign prostatic hyperplasia (BPH). J. Urol. 181, 528 (2009).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR82","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/2040622311423128","volume":"2","author":"N Shore","year":"2011","unstructured":"Shore, N. & Cowan, B. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther. Adv. Chronic Dis. 2, 377\u2013383 (2011).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"BFnrurol2015169_CR83","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1517\/13543780903555196","volume":"19","author":"N Shore","year":"2010","unstructured":"Shore, N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin. Investig. Drugs 19, 305\u2013310 (2010).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrurol2015169_CR84","unstructured":"Shore, N. et al. Multi-center Prospective Randomized Double-blind Study of Single-injection Transrectal NX-1207 in Men with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia, Annual Meeting of the South Central Section of the American Urological Association: Boston, 10 September (2007)."},{"key":"BFnrurol2015169_CR85","unstructured":"Cowan, B. et al. Outcome Analysis 8\u201319 Months After Single Treatment with Transrectal NX-1207 in Multi-center Prospective Blinded Randomized Placebo Controlled Study of Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia, Annual Meeting of the Mid- Atlantic Section of the American Urological Association: Bermuda, 18 October. (2007)."},{"key":"BFnrurol2015169_CR86","unstructured":"Shore, N. et al. A Prospective Randomized Two Dose Level Comparison of Single- injection Transrectal Intraprostatic NX-1207 and Finasteride in Men with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia, Annual Meeting of the North Central Section of the American Urological Association: Chicago, 25 September. (2008)."},{"key":"BFnrurol2015169_CR87","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2014)."},{"key":"BFnrurol2015169_CR88","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2014)."},{"key":"BFnrurol2015169_CR89","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrurol2015169_CR90","unstructured":"Nymox Pharmaceutical Corporation. nymox.com [online] , (2014)."},{"key":"BFnrurol2015169_CR91","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2014)."},{"key":"BFnrurol2015169_CR92","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/jnci\/djk065","volume":"99","author":"SA Williams","year":"2007","unstructured":"Williams, S. A. et al. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J. Natl Cancer Inst. 99, 376\u2013385 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrurol2015169_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1574-6968.1992.tb05881.x","volume":"5","author":"JT Buckley","year":"1992","unstructured":"Buckley, J. T. The channel-forming toxin aerolysin. FEMS Microbiol. Immunol. 5, 13\u201317 (1992).","journal-title":"FEMS Microbiol. Immunol."},{"key":"BFnrurol2015169_CR94","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/CAD.0b013e3280bad82d","volume":"18","author":"R Singh","year":"2007","unstructured":"Singh, R. et al. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18, 809\u2013816 (2007).","journal-title":"Anticancer Drugs"},{"key":"BFnrurol2015169_CR95","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1432-1033.1990.tb19466.x","volume":"194","author":"A Christensson","year":"1990","unstructured":"Christensson, A., Laurell, C. B. & Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755\u2013763 (1990).","journal-title":"Eur. J. Biochem."},{"key":"BFnrurol2015169_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/pros.20254","volume":"65","author":"C Savblom","year":"2005","unstructured":"Savblom, C. et al. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 65, 66\u201372 (2005).","journal-title":"Prostate"},{"key":"BFnrurol2015169_CR97","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000089731","volume":"76","author":"M Froehner","year":"2006","unstructured":"Froehner, M. et al. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol. Int. 76, 27\u201330 (2006).","journal-title":"Urol. Int."},{"key":"BFnrurol2015169_CR98","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.eururo.2010.11.024","volume":"59","author":"SR Denmeade","year":"2011","unstructured":"Denmeade, S. R. et al. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur. Urol. 59, 747\u2013754 (2011).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR99","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.juro.2012.11.003","volume":"189","author":"MM Elhilali","year":"2013","unstructured":"Elhilali, M. M. et al. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J. Urol. 189, 1421\u20131426 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR100","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2013)."},{"key":"BFnrurol2015169_CR101","unstructured":"US National Libraries of Medicine. ClinicalTrials.gov [online] , (2014)."},{"key":"BFnrurol2015169_CR102","unstructured":"FierceBiotech. fiercebiotech.com [online] , (2014)."},{"key":"BFnrurol2015169_CR103","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1464-410X.2011.10342.x","volume":"108","author":"HH Woo","year":"2011","unstructured":"Woo, H. H. et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int. 108, 82\u201388 (2011).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR104","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","volume":"190","author":"CG Roehrborn","year":"2013","unstructured":"Roehrborn, C. G. et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the, L.I.F.T. Study. J. Urol. 190, 2161\u20132167 (2013).","journal-title":"J. Urol."},{"key":"BFnrurol2015169_CR105","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/jsm.12333","volume":"11","author":"KT McVary","year":"2014","unstructured":"McVary, K. T. et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J. Sex Med. 11, 279\u2013287 (2014).","journal-title":"J. Sex Med."},{"key":"BFnrurol2015169_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urpr.2014.10.009","volume":"2","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn, C. G. et al. Durability of the prostatic urethral lift: two years results of the L.I.F.T. Study. Urol. Pract. 2, 1\u20137 (2015).","journal-title":"Urol. Pract."},{"key":"BFnrurol2015169_CR107","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.urology.2011.10.021","volume":"79","author":"PT Chin","year":"2012","unstructured":"Chin, P. T. et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79, 5\u201311 (2012).","journal-title":"Urology"},{"key":"BFnrurol2015169_CR108","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.eururo.2013.01.008","volume":"64","author":"TA McNicholas","year":"2013","unstructured":"McNicholas, T. A. et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur. Urol. 64, 292\u2013299 (2013).","journal-title":"Eur. Urol."},{"key":"BFnrurol2015169_CR109","first-page":"7094","volume":"21","author":"N Shore","year":"2014","unstructured":"Shore, N. et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can. J. Urol. 21, 7094\u20137101 (2014).","journal-title":"Can. J. Urol."},{"key":"BFnrurol2015169_CR110","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bju.12540","volume":"113","author":"AL Cantwell","year":"2014","unstructured":"Cantwell, A. L. et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 113, 615\u2013622 (2014).","journal-title":"BJU Int."},{"key":"BFnrurol2015169_CR111","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1743-6109.2011.02568.x","volume":"9","author":"HH Woo","year":"2012","unstructured":"Woo, H. H. et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Sex Med. 9, 568\u2013575 (2012).","journal-title":"J. Sex Med."},{"key":"BFnrurol2015169_CR112","doi-asserted-by":"publisher","unstructured":"S\u00f8nksen, J. et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur. Urol. http:\/\/dx.doi.org\/10.1016\/j.eururo.2015.04.024 .","DOI":"10.1016\/j.eururo.2015.04.024"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.169","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2015.169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:53:47Z","timestamp":1748512427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2015.169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":112,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFnrurol2015169"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2015.169","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]},"assertion":[{"value":"21 July 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}